Switching to bedaquiline for treatment of rifampicin-resistant tuberculosis in South Africa: A retrospective cohort analysis.
Tara C BoutonMargaretha de VosElizabeth J RaganLaura F WhiteLeonie Van ZylDanie TheronC Robert HorsburghRobin M WarrenKaren R JacobsonPublished in: PloS one (2019)
South Africa led the world with guidelines on bedaquiline (BDQ) use as a single drug substitution to manage rifampin resistant tuberculosis regimen toxicity. We examined reasons for giving BDQ in a retrospective cohort: >75% of patients were switched to BDQ for toxicity (ototoxicity or renal dysfunction) rather than drug resistance.
Keyphrases
- south africa
- mycobacterium tuberculosis
- drug resistant
- multidrug resistant
- oxidative stress
- end stage renal disease
- pulmonary tuberculosis
- hiv positive
- ejection fraction
- newly diagnosed
- chronic kidney disease
- hiv aids
- adverse drug
- prognostic factors
- patient reported outcomes
- hepatitis c virus
- drug induced
- hiv infected
- replacement therapy